How does a metallofactor in Hepatitis B viral protein X orchestrate pathogenesis and liver cancer
How does a metallofactor in Hepatitis B viral protein X orchestrate pathogenesis and liver cancer
批准号:
10798758
负责人:
Maria-Eirini Pandelia
金额:
$3.35万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-07-05 至 2024-06-30
关键词:
AffectAntineoplastic AgentsAutomobile DrivingBindingBinding ProteinsBiologicalCell physiologyChemicalsCirrhosisClinicalCysteineDevelopmentDiseaseDisulfidesElectron TransportEtiologyGenerationsGenotypeGleanGoalsHepatitis BHepatitis B VirusHomeostasisHumanIronKnowledgeLigandsLinkLiverLocationMalignant NeoplasmsMalignant neoplasm of liverMediatingMetalloproteinsMethodsMolecularMolecular ConformationMutationNatureOncogenicOxidation-ReductionPathogenesisPathway interactionsPhysiologicalPlayPrimary carcinoma of the liver cellsProcessProtein ConformationProteinsResearchRoleSequence DeletionSolubilityStructureTestingTimeTranslatingViralViral ProteinsViruscellular targetingchronic infectioncofactorinnovationnovel strategiesnovel therapeuticsprotein foldingprotein protein interactionprotein structureresponsescaffoldtraffickingtumorigenic
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
Chronic infection by the Hepatitis B virus (HBV) is a leading cause of human cancer worldwide, and is
strongly associated with development of cirrhosis and hepatocellular carcinoma (HCC). The 17-kDa HBx protein
of HBV is a causative tumorigenic agent and affects multiple cellular processes, either on its own or together
with the proteins it targets. Though the oncogenic potential of HBx has been demonstrated, neither its structure
nor the molecular mechanisms by which it mediates liver-associated diseases are known. The major obstacles
have been the sparing solubility, lack of significant homology to characterized proteins and intrinsic disorder. Our
studies have succeeded in obtaining HBx in highly soluble forms and for the first time shown that HBx is an [Fe-
S]-binding protein. Our long-term goal is to establish the chemical nature of the cofactor and its involvement in
driving protein conformation and reactivities, ultimately translating this molecular and structural knowledge to
HBxs’ extended functional repertoire. Our central hypothesis is that the [Fe-S] cluster is a common feature of
HBxs across all genotypes. We propose that the [Fe-S] cofactor confers structure in an otherwise disordered
protein and modulates protein reactivity and interactions by (at least) three distinct pathways: a) protein-protein
interactions, by changing the oligomeric or conformational status of HBx, b) redox mechanisms involving either
i) electron transfer processes to cofactors of target proteins or ii) regulatory processes as a response to cellular
redox status and generation of ROS, c) Fe- or [Fe-S]- transfer mechanisms, by which HBx can act as a scaffold
for iron-trafficking to regulate iron homeostasis and downstream molecular pathways. Our specific aims will test
these hypotheses by: (Aim 1) establishing the biologically relevant form of the cofactor, and if both observed
[4Fe] (stable) and [2Fe] (transient) forms are physiologically relevant. We will identify the cluster ligands, cysteine
residues likely involved in disulfides and examine how clinical mutations and large sequence deletions may affect
the cofactor and thus HBx function. (Aim 2) Establish the type, location and effects of the [Fe-S] cluster on the
protein structure (disorder-to-order transition) and whether cluster incorporation drives protein folding. If
successful, this step will set the stage for solving by solution NMR methods the highly sought structure of HBx,
either on its own or together with cellular binding partners. (Aim 3) Establish a link between the type and redox
form of the [Fe-S] cofactor and HBx biological activity. The expected overall impact of this innovative proposal
is that it will fundamentally advance our understanding of HBx on the molecular and structural level, which is
currently missing. Because HBx is a potential target for the development of anti-cancer drugs, determining the
role(s) of the [Fe-S] cofactor and the linked structure/function relationships, will glean its part in viral-induced
pathogenesis and offer new therapeutic avenues.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
How does a metallocofactor in the Hepatitis B viral protein X orchestrate pathogenesis and liver cancer?
-
批准号:10389582
-
项目类别:
-
资助金额:$6.76万
-
财政年份:2019
-
负责人:Maria-Eirini Pandelia
-
依托单位:
How does a metallocofactor in the Hepatitis B viral protein X orchestrate pathogenesis and liver cancer?
-
批准号:10170379
-
项目类别:
-
资助金额:$33.81万
-
财政年份:2019
-
负责人:Maria-Eirini Pandelia
-
依托单位:
How does a metallocofactor in the Hepatitis B viral protein X orchestrate pathogenesis and liver cancer?
-
批准号:10428574
-
项目类别:
-
资助金额:$33.81万
-
财政年份:2019
-
负责人:Maria-Eirini Pandelia
-
依托单位:
How does a metallocofactor in the Hepatitis B viral protein X orchestrate pathogenesis and liver cancer?
-
批准号:10642956
-
项目类别:
-
资助金额:$33.81万
-
财政年份:2019
-
负责人:Maria-Eirini Pandelia
-
依托单位:
Functional diversification of the HD-superfamily; the Hydrolase/Oxygenase Dilemma
-
批准号:8921236
-
项目类别:
-
资助金额:$2.69万
-
财政年份:2014
-
负责人:Maria-Eirini Pandelia
-
依托单位:
Functional diversification of the HD-superfamily; the Hydrolase/Oxygenase Dilemma
-
批准号:9271972
-
项目类别:
-
资助金额:$24.58万
-
财政年份:2014
-
负责人:Maria-Eirini Pandelia
-
依托单位:
Functional diversification of the HD-superfamily; the Hydrolase/Oxygenase Dilemma
-
批准号:8767627
-
项目类别:
-
资助金额:$8.06万
-
财政年份:2014
-
负责人:Maria-Eirini Pandelia
-
依托单位:
海外基金